CBD Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Cannabidiol Market Report is Segmented by Source (Hemp and Marijuana), End Use (Pharmaceuticals, Wellness & Personal Use, and More), Product Form (Oils & Tinctures, Capsules & Softgels, and More), Distribution Channel (Hospital & Specialty Pharmacies, Retail Stores, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Cannabidiol (CBD) Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Cannabidiol (CBD) Market with other markets in Healthcare Industry

Cannabidiol (CBD) Market Analysis by Mordor Intelligence

The Cannabidiol Market size is estimated at USD 10.04 billion in 2025, and is expected to reach USD 21.34 billion by 2030, at a CAGR of 16.28% during the forecast period (2025-2030).

Rapid pharmaceutical‐grade innovation is steering the CBD market from niche wellness toward mainstream therapeutic and consumer applications. The pharmaceutical segment led with 41.53% revenue in 2024 as regulators, prescribers, and patients accepted evidence-backed CBD medicines. North America retained a 47.21% revenue lead, but Asia-Pacific is projected to post a 20.32% CAGR on the back of Japan’s and Australia’s regulatory reforms. Imminent U.S. rescheduling of cannabis to Schedule III could unlock FDA-approved cannabinoid drugs for pharmacies, while nanoemulsion and other fast-acting delivery technologies widen the addressable base for ingestibles and topicals. Intensifying consolidation—exemplified by Canopy Growth’s acquisition of Wana and Jetty—signals that brand portfolios and proprietary IP will dictate competitive advantage in the CBD market.

Key Report Takeaways

  • By source, hemp accounted for a 55.71% share of the CBD market in 2024, while marijuana-derived CBD is set to grow at an 18.92% CAGR between 2025 and 2030. 
  • By end use, the pharmaceutical segment captured 41.53% of CBD market share in 2024; pet care is projected to expand at a 32.57% CAGR through 2030. 
  • By product form, oils & tinctures held 38.11% of CBD market share in 2024; gummies & confectionery are forecast to post a 30.78% CAGR to 2030. 
  • By distribution channel, retail stores led with a 46.81% revenue share in 2024; e-commerce is advancing at a 22.43% CAGR. 
  • By geography, North America commanded 47.21% of 2024 revenue, whereas Asia-Pacific is estimated to chart a 20.32% CAGR through 2030.

Segment Analysis

By Source: Hemp Commands Volume While Marijuana Gains Value Momentum

Hemp-derived products captured 55.71% of 2024 revenue as favorable legislation and established farming supply chains ensured consistent input quality. The CBD market size for hemp formats is projected to expand at a mid-teens CAGR as ingestibles and cosmetics widen consumer reach. Demand for marijuana-derived extracts, however, is forecast to climb 18.92% annually between 2025 and 2030 as the entourage effect gains clinical backing and potential U.S. Schedule III status relaxes research barriers. The CBD market welcomes hybrid extraction methods such as Smokenol™ that capture smoke-borne terpenes, blurring traditional source distinctions and enabling tailored cannabinoid ratios for formulators.

Hemp’s legal clarity supports multinational retailers that require THC-free inventory, especially in Europe and parts of Asia. Marijuana-sourced CBD appeals to prescription channels where trace THC content is permissible under pharmacopoeia standards. As pharmaceutical trials broaden beyond epilepsy to pain and anxiety, vertically integrated cultivators with both hemp and marijuana licenses are best positioned to supply diversified APIs at scale.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End Use: Pharmaceuticals Lead Revenue; Pet Care Races Ahead

Pharmaceutical applications generated 41.53% of 2024 sales, buoyed by Epidiolex’s USD 198.7 million Q1 2024 revenue and continued expansion into tuberous sclerosis and Lennox-Gastaut syndrome indications. This dominance translates into the highest CBD market share across end uses, with payers increasingly reimbursing cannabinoid prescriptions. The CBD market size for pet care, however, is forecast to advance at 32.57% CAGR as owners adopt functional chews and oils for arthritis, anxiety, and postoperative recovery in companion animals. Veterinary practitioners cite growing peer-reviewed evidence for canine osteoarthritis pain reduction, underpinning demand for GMP-grade tinctures.

Wellness and personal-use SKUs continue evolving toward targeted benefits. “Stay Asleep” CBN plus CBD gummies address the 67% of adults reporting sleep issues, illustrating how broadened cannabinoid profiles capture additional consumer need states. Such functional diversification boosts category resiliency against raw-material oversupply shocks.

By Product Form: Oils & Tinctures Retain Pole Position While Gummies Surge

Consumers gravitate toward oils and tinctures for dosage flexibility, granting the format 38.11% revenue in 2024. Precise droppers and minimal excipients appeal to medically supervised regimens, sustaining trust among health-care providers. Gummies and confectionery, projected to grow 30.78% annually to 2030, attract first-time users who prefer familiar snack formats and tastemasked profiles. Alcohol-replacement trends further energize the CBD market size for gummies; Australian consumers cite cannabis gummies’ hangover-free benefit when choosing them over beer.

Advanced nanoemulsion shortens edible onset to under 30 minutes and boosts bioavailability, eroding oils’ speed advantage and expanding gummies’ evening-winding-down occasions. Topicals are likewise adopting water-soluble nano-drops to lift dermal absorption, underpinning the premiumization of cosmetic SKUs.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Brick-and-Mortar Still Commands Trust; E-Commerce Accelerates

Retail stores controlled 46.81% of 2024 revenue as shoppers value live staff guidance and instant product access. Pharmacies, wellness chains, and grocery banners broaden shelf space following clearer local statutes. Nonetheless, e-commerce is on a 22.43% CAGR trajectory. One-click replenishment and discrete delivery resonate with chronic-condition patients wary of stigma. ChatCBDW AI bots replicate dispensary expertise, resolving dosage and interaction questions and lifting conversion rates.

Convenience retailers like Circle K expand pilot kiosks stocked with broad-spectrum gummies and seltzers, while Yesway’s Feel Good Shop+ curates impulse-purchase SKUs adjacent to energy drinks. Potential U.S. Schedule III rescheduling would channel FDA-approved cannabinoid drugs into hospital and specialty pharmacies, cementing medical supply chains that align with payer reimbursement and physician prescribing workflows.

Geography Analysis

North America remained the epicenter of the CBD market with 47.21% revenue in 2024. Imminent federal rescheduling is expected to shrink illicit channels, reduce possession arrests, and catalyze double-digit investment in clinical trials. Consolidation is also reshaping the landscape; Cresco Labs’ USD 2 billion acquisition of Columbia Care exemplifies scale pursuit under tightening capital markets. Canada remains the hub for GMP-grade cannabinoid research, while Mexico’s pending secondary regulations could open Latin America’s most populous market.

Asia-Pacific is projected to post a 20.32% CAGR through 2030, propelled by Japan’s landmark reforms that legalize medical cannabinoid products. China’s beauty sector leads CBD adoption via cross-border e-commerce, with luxury serums commanding premium pricing. Australia’s Special Access Scheme facilitates prescription CBD for anxiety and insomnia, building physician familiarity and patient loyalty.

Europe presents sizable upside as Germany moves to decriminalize adult-use cannabis, lifting investor sentiment and reviving Canopy Growth’s European restructuring. The European Monitoring Centre for Drugs and Drug Addiction is drafting a harmonized CBD safety framework, addressing current patchworks that hamper trade. The UK emphasizes novel-food authorizations, fostering white-label supply chains. France and Italy accelerate medical-cannabis trials, stimulating pharmaceutical demand for GMP isolate and distillate.

Cannabidiol (CBD) Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The CBD market shows moderate concentration; top multinationals pursue vertical integration to control genetics, extraction, and branded distribution. Canopy Growth’s 2024 purchase of Wana and Jetty refocuses its U.S. strategy on high-margin edibles and solventless concentrates. CV Sciences’ USD 1.4 million acquisition of Extract Labs brings in-house manufacturing and CBD-isolate supply, improving gross margin resilience.

Pharma players anchor the prescription segment: Jazz Pharmaceuticals leverages GW’s IP estate to defend Epidiolex exclusivity while exploring cannabidiol combinations with standard anti-epileptics. Patents for novel delivery, including Real Isolates’ Smokenol, signal rising R&D intensity and potential litigation barriers to late entrants. Meanwhile, Radicle Science and Open Book Extracts co-develop rigorously tested consumer products, responding to retailer and consumer calls for transparency.

Startups exploit white spaces in pet wellness, beauty, and sleep aid niches. Capital inflows favor firms with differentiated technology or proprietary genetics, leaving commodity tincture sellers vulnerable amid raw-material price compression. As branding dictates shelf impact, marketing spend shifts toward clinical substantiation and QR-code traceability to reassure cautious shoppers.

Cannabidiol (CBD) Industry Leaders

  1. Cannoid LLC

  2. Medical Marijuana, Inc

  3. Nuleaf Naturals LLC

  4. Elixinol Wellness Ltd.

  5. Aurora Cannabis Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Cannabidiol (CBD) Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: Tilray Brands reported a 9% year-over-year increase in net revenue for Q2 2025, reaching USD 211 million, with a gross profit increase of 29% to USD 61 million.
  • January 2025: Canopy Growth reported a 54% reduction in Adjusted EBITDA loss to USD 6 million and improved free cash flow by 16%, despite a 9% year-over-year decline in net revenue to USD 63.0 million.
  • December 2024: Charlotte's Web provided an update on DeFloria's Phase 1 clinical trial results for AJA001, a multi-compound hemp extract developed for treating autism spectrum disorder, demonstrating safety and tolerability.
  • December 2024: Vireo Growth Inc. announced a USD 397 million merger with Proper Brands and three other cannabis companies, expanding its operations across several states, including Missouri, Nevada, and Utah.

Table of Contents for Cannabidiol (CBD) Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Chronic Pain Management Driving Prescription CBD Uptake
    • 4.2.2 Regulatory Pathways Opening for Over-the-Counter CBD in Pharmacy Chains
    • 4.2.3 Adoption of CBD-Infused Functional Foods Among Aged Population
    • 4.2.4 Increasing Awareness among Consumers Regarding Health
    • 4.2.5 Rising Integration of CBD in Cosmetic and Skincare Formulations
    • 4.2.6 Expansion of Online Retail Platforms and E-Commerce Penetration
  • 4.3 Market Restraints
    • 4.3.1 Strict Regulation on the Cannabidiol Products
    • 4.3.2 Price Compression from Oversupply of Hemp Biomass
    • 4.3.3 Banking & Insurance Restrictions on CBD Start-ups in Developing Countries
    • 4.3.4 Lack of Uniform Global Regulatory Frameworks and Labeling Standards
  • 4.4 Regulatory Landscape
  • 4.5 Porter’s Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Source
    • 5.1.1 Hemp
    • 5.1.2 Marijuana
  • 5.2 By End Use
    • 5.2.1 Pharmaceuticals
    • 5.2.2 Wellness & Personal Use
    • 5.2.3 Food & Beverages
    • 5.2.4 Cosmetics & Skin Care
    • 5.2.5 Pet Care
    • 5.2.6 Nutraceuticals & Supplements
  • 5.3 By Product Form
    • 5.3.1 Oils & Tinctures
    • 5.3.2 Capsules & Softgels
    • 5.3.3 Gummies & Confectionery
    • 5.3.4 Topicals / Skin Care
    • 5.3.5 Vape Products
    • 5.3.6 Others
  • 5.4 By Distribution Channel
    • 5.4.1 Hospital & Specialty Pharmacies
    • 5.4.2 Retail Stores
    • 5.4.3 E-commerce
    • 5.4.4 Medical Dispensaries
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Canopy Growth Corporation
    • 6.3.2 Charlotte’s Web Holdings Inc.
    • 6.3.3 Jazz Pharmaceuticals plc (GW Pharmaceuticals)
    • 6.3.4 Tilray Brands Inc.
    • 6.3.5 Aurora Cannabis Inc.
    • 6.3.6 CV Sciences Inc.
    • 6.3.7 Medical Marijuana Inc.
    • 6.3.8 Elixinol Wellness Ltd.
    • 6.3.9 Endoca BV
    • 6.3.10 Nuleaf Naturals LLC
    • 6.3.11 Pharmahemp d.o.o.
    • 6.3.12 Isodiol International Inc.
    • 6.3.13 Medterra CBD
    • 6.3.14 Green Roads LLC
    • 6.3.15 Honest Paws LLC
    • 6.3.16 Pet Releaf
    • 6.3.17 Lazarus Naturals
    • 6.3.18 HempMeds Brasil
    • 6.3.19 Holistic Hound
    • 6.3.20 Kazmira LLC

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Cannabidiol (CBD) Market Report Scope

As per the scope of this report, Cannabidiol (CBD) is a chemical compound obtained from marijuana and hemp plants and is commonly used for medical purposes. The Cannabidiol (CBD) Market is segmented by Source (Hemp and Marijuana ), Application (Anxiety/ Stress, Neurological Conditions, Skin Care, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.

By Source Hemp
Marijuana
By End Use Pharmaceuticals
Wellness & Personal Use
Food & Beverages
Cosmetics & Skin Care
Pet Care
Nutraceuticals & Supplements
By Product Form Oils & Tinctures
Capsules & Softgels
Gummies & Confectionery
Topicals / Skin Care
Vape Products
Others
By Distribution Channel Hospital & Specialty Pharmacies
Retail Stores
E-commerce
Medical Dispensaries
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Source
Hemp
Marijuana
By End Use
Pharmaceuticals
Wellness & Personal Use
Food & Beverages
Cosmetics & Skin Care
Pet Care
Nutraceuticals & Supplements
By Product Form
Oils & Tinctures
Capsules & Softgels
Gummies & Confectionery
Topicals / Skin Care
Vape Products
Others
By Distribution Channel
Hospital & Specialty Pharmacies
Retail Stores
E-commerce
Medical Dispensaries
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current global CBD market size?

The CBD market size stands at USD 10.04 billion in 2025.

What is the forecast compound annual growth rate (CAGR) for the CBD market to 2030?

The market is projected to expand at a 16.28% CAGR and reach USD 21.34 billion by 2030.

Which application segment holds the largest CBD market share?

The pharmaceutical segment led with 41.53% revenue share in 2024.

Which geographic region is expected to grow fastest through 2030?

Asia-Pacific is forecast to post a 20.32% CAGR, the highest among all regions.

What technology is improving CBD product bioavailability and onset time?

Nanoemulsion technology shortens onset to 15–30 minutes and boosts absorption.

How could U.S. Schedule III rescheduling affect CBD pharmaceuticals?

Rescheduling would allow FDA approval of cannabinoid drugs for pharmacies, expanding prescription access and accelerating R&D investment.

Page last updated on: July 15, 2025

Cannabidiol (CBD) Market Report Snapshots